uploads/2018/05/Chart-006-3-1.jpg

Pfizer’s Products with Declining Revenues in Q1 2018

By

Updated

Products with declining sales in the first quarter

Pfizer’s (PFE) portfolio includes some products that are losing market share due to competition from other products in the market. These products include Prevnar 13, Inlyta, Toviaz, Enbrel (outside the United States and Canada), BeneFix, Premarin, EpiPen, Tygacil, Precedex, Celebrex, Vfend, Lyrica, Zyvox, Revatio, Pristiq, and Viagra.

The above chart shows revenues from products reporting a decrease in revenues since 1Q17.

Article continues below advertisement

Negative growth products

Pfizer’s revenues were affected by lower sales of the following drugs:

  • Enbrel, the blockbuster drug, reported a 14% decline to $506 million in the first quarter. Revenues included sales from outside the United States and Canada.
  • BeneFix’s revenues declined 2% to $147 million in the first quarter, driven by a 13% decline in international sales to $79 million, offset by a 16% growth in US sales to $68 million.
  • Celebrex reported a 17% decline in revenues to $145 million in the first quarter, driven by a 49% decline in US sales to $16 million and an 11% decline in revenues to $129 million.
  • EpiPen, Mylan’s (MYL) blockbuster drug, contains a drug manufactured by Pfizer. Pfizer reported a 36% decline in revenues for EpiPen to $52 million, driven by lower sales inside and outside the US markets.
  • Inlyta, an oncology drug, reported a 13% decline in revenues to $74 million in the first quarter, driven by a 9% decline in US sales to $28 million and a 15% decline in international sales to $46 million.
  • Viagra reported a 45% decline in revenues to $187 million in the first quarter, driven by a 63% decline in US sales to $88 million, substantially offset by a 2% growth in international sales to $99 million.
  • Zyvox reported an 11% decline in revenues to $68 million in the first quarter, driven by a 7% decline in international sales to $63 million and a 40% decline in US sales to $6 million.

The Health Care Select Sector SPDR ETF (XLV) holds 6.6% of its total investments in Pfizer (PFE), 3.6% in Amgen (AMGN), 2.7% in Gilead Sciences (GILD), and 0.6% in Mylan (MYL).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!

Advertisement

More From Market Realist